{
  "symbol": "REGN",
  "year": 2023,
  "period": "Q1",
  "curated_text": "Symbol: REGN. Year: 2023. Period: Q1. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: FDA, DME, Company, Libtayo, the IO Collaboration, Dupixent, the Antibody Collaboration, LCA, Regeneron, the Antibody License and Collaboration Agreement, Bayer Collaboration Revenue, Total Bayer, Bayer, Reimbursement of development, Roche Collaboration Revenue Three Months Ended, Roche, Change Research, Change Direct, 11.6, Reimbursement of research and, the Sanofi Antibody Collaboration. Context excerpt: competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits in connection with commercialization of antibodies $ 863.0 $ 551.1 $ 2,250.6 $ 1,463.0 Sales-based milestones earned 50.0 \u2014 50.0 50.0 Reimbursement for manufacturing of commercial supplies (a) 151.5 160.5 506.0 466.8 Other \u2014 (0.2) \u2014 28.7 Total Antibody 1,064.5 711.4 2,806.6 2,008.5 Total Immuno-oncology (b) \u2014 \u2014 \u2014 11.3 Total Sanofi collaboration revenue $ 1,064.5 $ 711.4 $ 2,806.6 $ 2,019.8",
  "competition_summary": [
    {
      "competitor": "FDA",
      "mentions": 2,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "DME",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Company",
      "mentions": 5,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Libtayo",
      "mentions": 3,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "the IO Collaboration",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Dupixent",
      "mentions": 4,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "the Antibody Collaboration",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "LCA",
      "mentions": 2,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Regeneron",
      "mentions": 11,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "the Antibody License and Collaboration Agreement",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Bayer Collaboration Revenue",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Total Bayer",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Bayer",
      "mentions": 6,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Reimbursement of development",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Roche Collaboration Revenue Three Months Ended",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Roche",
      "mentions": 3,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Change Research",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Change Direct",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "11.6",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "Reimbursement of research and",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    },
    {
      "competitor": "the Sanofi Antibody Collaboration",
      "mentions": 1,
      "context": "competition. In August 2023, the FDA approved EYLEA HD for the treatment of patients with wAMD, DME, and DR. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended September 3"
    }
  ]
}